| 67.315 -0.245 (-0.36%) | 10-29 14:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 89.71 | 1-year : | 104.78 |
| Resists | First : | 76.8 | Second : | 89.71 |
| Pivot price | 70.11 |
|||
| Supports | First : | 62.8 | Second : | 54.15 |
| MAs | MA(5) : | 67.49 |
MA(20) : | 69.07  |
| MA(100) : | 52.02 |
MA(250) : | 49.98 |
|
| MACD | MACD : | 2.3 |
Signal : | 3.3 |
| %K %D | K(14,3) : | 20.8 |
D(3) : | 21.9 |
| RSI | RSI(14): 54.4 |
|||
| 52-week | High : | 76.8 | Low : | 38.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TARS ] has closed above bottom band by 23.1%. Bollinger Bands are 1.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 68.5 - 68.88 | 68.88 - 69.19 |
| Low: | 65.72 - 66.26 | 66.26 - 66.7 |
| Close: | 66.76 - 67.57 | 67.57 - 68.22 |
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
Tue, 28 Oct 2025
Tarsus Pharmaceuticals, Inc. to Host Live Webcast for Q3 2025 Financial Results and Corporate Update - Quiver Quantitative
Tue, 28 Oct 2025
Tarsus (NASDAQ: TARS) sets Nov. 4 webcast to share third‑quarter results at 1:30 p.m. PT - Stock Titan
Sun, 26 Oct 2025
Tarsus Pharmaceuticals' (TARS) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Sat, 18 Oct 2025
Market Participants Recognise Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Revenues Pushing Shares 41% Higher - Sahm
Tue, 14 Oct 2025
Tarsus Pharmaceuticals (TARS) Is Up 15.1% After Xdemvy Demand and Pipeline Advances What's Changed - Sahm
Wed, 08 Oct 2025
Why Tarsus Pharmaceuticals (TARS) Is Up 21.6% After Xdemvy’s Uptake and New Trial Announcements—And What's Next - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 42 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 3.1 (%) |
| Held by Institutions | 115 (%) |
| Shares Short | 7,030 (K) |
| Shares Short P.Month | 7,630 (K) |
| EPS | -2.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.88 |
| Profit Margin | -31.2 % |
| Operating Margin | -21.7 % |
| Return on Assets (ttm) | -14.1 % |
| Return on Equity (ttm) | -31.5 % |
| Qtrly Rev. Growth | 151.5 % |
| Gross Profit (p.s.) | 5.13 |
| Sales Per Share | 7 |
| EBITDA (p.s.) | -2.29 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -81 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -29.43 |
| PEG Ratio | 0 |
| Price to Book value | 8.55 |
| Price to Sales | 9.62 |
| Price to Cash Flow | -35.18 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|